A combination device targeted toward stymying iron beta plus protein symplex build up in neural receptors.
Neurodegenerative diseases diagnosis has been ramping up at a faster rate in the last three years. Positioned to outpace cardiovascular cancers and diseases by 2045, aligning targeting for neuro-diseases are starting to become critically important.
Currently in phase I safety trials, Project Apollo will be presented in numerous publications, events, and conferences in 2019.
Disease profiles of yield toward effectivity of product efficacy. Project Apollo is geared toward aligning a bridge toward multi-targeting profiles as a treatment method.